CPhI China 2019 was held successfully in Shanghai, China from June 18th-20th. We Sinopeg sent a very professional sales team to participate this exhibition. Our booth Number is W4F21. During the exhibition, we had very deep disscuion with old partner, and customers from all over the world came to  consult the company's products，we obtained the approval and praise from our customers. Looking forward to see you again next year, CPhI China 2020 in Shanghai.

Warmly welcome you to visit our booth 1D73 in API  (Hangzhou) from May. 8th to May. 10th, 2019. Exhibition name: the 82nd API China- China international pharmaceutical raw materials, intermediates, packaging, equipment fair. Booth number:1D73 Time: May 8-10,2019 Venue: Hangzhou international expo center We provided a wealth of polyethylene glycol derivatives, side chains of hypoglycemic drugs (Semaglutide side chain, Liraglutide side chain, Insulin Detemir side chain, Insulin Deglutide chain), polyethylene glycol block copolymers, polyethylene glycol phospholipids, etc. Welcome to our booth.

Welcome to visit us at

We are delighted to invite you to visit our booth at TIDES USA, taking place from May 14th to 17th, 2024 in Boston, USA. The exhibition booth number for SINOPEG is 911. TIDES USA serves as an excellent platform for networking, sharing knowledge, and exploring cutting-edge innovations. At our booth #911, you can expect an engaging and informative experience. We have prepared a wide range of exciting content to share with you, including ADC/PROTAC PEG Linkers, GLP-1 Intermediates, Block Copolymers, etc. We believe these offerings will spark interesting discussions and provide valuable insights into the latest developments in the industry. Whether you are looking to collaborate, explore potential partnerships, or simply exchange ideas, our team will be available at booth 911 to meet and discuss further. We kindly request that you mark your calendar and reserve some time to visit our booth during the exhibition. We value your presence and look forward to the opportunity to connect with you. Should you have any inquiries or require further information, please do not hesitate to contact us. Thank you for considering our invitation, and we hope to see you at TIDES USA. For more product information, please contact us at: US Tel: 1-844-782-5734 US Tel: 1-844-QUAL-PEG CHN Tel: 400-918-9898 Email: sales@sinopeg.com

Lipid nanoparticle (LNP) delivery systems are widely used in the fields of gene therapy and vaccines.However, to achieve effective gene delivery and vaccine delivery, not only suitable carriers and nucleic acids or antigens need to be selected, but also excipients for LNP delivery systems are needed.These excipients play a key role in stability, transparency, protective effect, and charge capacity. Firstly, stability is an important characteristic of excipients for LNP delivery systems.Excipients interact with lipid components, increasing the stability of LNP.For example, polyethylene glycol (PEG) is one of the commonly used excipients, which can form a stable layer of polymer by covering the surface of LNP.This polymer layer helps to reduce protein and cell adsorption and provides additional stability, thereby prolonging the circulation life of LNP. Secondly, transparency is an important factor to be considered when designing LNP delivery systems.Transparency can affect the preparation of LNP and the visualization of the internal structure.Therefore, excipients are usually selected for their characteristics of lower absorption and scattering of light to obtain clear imaging and accurate structural analysis. In addition, excipients for LNP delivery systems can also provide protection, protecting nucleic acids or antigens from degradation. For example, cholesterol is a common excipient that can be inserted into LNP to form a barrier that protects the nucleic acid or antigen.This protective layer can prevent the nucleic acid or antigen from being attacked by enzymes and help improve delivery efficiency and immune activation. In addition, charge is also an important characteristic of excipients.Charge can affect the interaction between LNP and target cells and delivery efficiency.For example, some excipients can regulate the charge state on the surface of LNP to improve its adsorption and cell uptake, thus improving delivery effect. In summary, excipients in LNP delivery systems play an important role in gene therapy and vaccine research.By selecting appropriate excipients, the stability, transparency, protective effect and charge of LNP can be optimized to achieve efficient gene delivery and vaccine delivery.Researchers will continue to develop new excipients to further improve the performance of LNP delivery systems and promote the development of gene therapy and vaccine research. Lipids that has been registered with DMF: Ionizable Cationic Lipid DLin-MC3-DMA SM-102 (HUO) ALC-0315 (DHA) DHA-1 (ALC-0315 analogue) PEGylated Lipids mPEG-DMG-2K ALC-0159 (mPEG-DTA) mPEG-DTA-1-2K (ALC-0159 analogue) Neutral Phospholipid DSPC DOPE Sterol Lipids Cholesterol (Plant) Click here for more lipid products

We are delighted to announce that SINOPEG will be participating in the LNP Formulation & Process Development Summit 2024 Agreement, scheduled to take place on April 29, 2024, in Boston, USA. This prestigious exhibition offers a unique platform for industry professionals to gather and exchange valuable insights on the latest advancements in LNP formulation and process development. We extend a warm welcome to everyone interested in this field to join us at this exciting event. Powered by latest developments with LNP CRISPR gene editing in the lungs, Bayer and Acuitas uniting to strengthen their Gene Therapy portfolio, new biotech ReNAgade Therapeutics launching with $300m Series A financing, lipid nanoparticles continue to dominate biopharma pipelines in 2024 and beyond as the most successful non-viral delivery vehicle to date. Moving into novel applications from gene therapy and cell therapy, and new disease indications from oncology to rare disease, LNP are equipping scientists with the ability to deliver transformative medicines to patients. With industry at a critical inflection point as a need to demonstrate clinical advancements for confidence to advance pipelines in 2024, the 3rd LNP Formulation & Process Development Summit will unite again in April with 4 tracks of carefully curated content as the industry’s one-stop-shop to evaluate and optimize LNPs end-to-end development for your given target of interest. *60+ expert speakers pioneering the next generation of LNP drug products *Content from early-stage discovery through the commercialized manufacture at large scale *A plethora of payloads, disease indications and route of administration *8 in-depth workshops, LNP 101 focus day, IP Patenting & Commercial Partnerships focus day, and 10+ hours of dedicated networking *Countless new topics, new speakers and new companies Date: April 29, 2024 Location:Boston, USA For more information and registration details, please visit the official website of the LNP Formulation & Process Development Summit 2024 Agreement. The LNP Formulation & Process Development Summit 2024 Agreement in Boston is an event not to be missed for professionals in the field of LNP formulation and process development.  We look forward to welcoming you to this exciting exhibition, where we can collectively contribute to the advancement of this rapidly evolving field. See you there!